2
Clinical Trials associated with Denosumab biosimilar(Biocon Biologics)A Randomized, Double-Blind, Multicenter, Parallel-Arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
This is a randomized, double-blind, multicenter, parallel-arm, Phase 3 study to compare the efficacy, PK (Pharmacokinetic), PD (Pharmacodynamic), safety, and immunogenicity of Bmab 1000 and Prolia® in postmenopausal women with osteoporosis
A Randomized, Double-blind, Two-arm, Single-dose, Parallel-Group Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Bmab 1000 and Prolia® in Normal Healthy Volunteers
This study is to compare the Pharmacokinetics, Pharmacodynamics, safety, and tolerability of Bmab 1000 and Prolia® in normal healthy volunteers.
100 Clinical Results associated with Denosumab biosimilar(Biocon Biologics)
100 Translational Medicine associated with Denosumab biosimilar(Biocon Biologics)
100 Patents (Medical) associated with Denosumab biosimilar(Biocon Biologics)
100 Deals associated with Denosumab biosimilar(Biocon Biologics)